Zai Lab is a commercial-stage biopharmaceutical company headquartered in Greater China that discovers, develops, and commercializes innovative therapies in oncology, immunology, neuroscience, and infectious disease. The company generates revenue by commercializing approved products in Greater China through exclusive partnerships with leading global biopharmaceutical companies and its own sales infrastructure, targeting inclusion on national reimbursement lists and supplemental insurance coverage to expand patient access. Zai Lab maintains an R&D pipeline of internally developed and partnered assets in late-stage development while operating GMP-compliant manufacturing facilities and pursuing profitability through a three-pillar strategy of accelerated R&D investment, pipeline expansion via collaborations, and commercial excellence.